Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adem Y Dawed

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Communications Medicine|October 4, 2023
Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic reviewKatherine G Young, Eram Haider McInnes, Robert J Massey, et al.
Diabetologia|March 5, 2022
Young-onset diabetes in Asian Indians is associated with lower measured and genetically determined beta cell functionMoneeza K Siddiqui, Ranjit Mohan Anjana, Adem Y Dawed, et al.
Diabetologia|April 26, 2022
Correction to: Young-onset diabetes in Asian Indians is associated with lower measured and genetically determined beta cell functionMoneeza K Siddiqui, Ranjit Mohan Anjana, Adem Y Dawed, et al.
Diabetes Care|March 20, 2019
Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by <i>SLC29A4</i>) and Organic Cation Transporter 1 (OCT1) (Encoded by <i>SLC22A1</i>) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT StudyAdem Y Dawed, Kaixin Zhou, Nienke van Leeuwen, et al.
Nature Medicine|May 9, 2022
Heterogeneity in phenotype, disease progression and drug response in type 2 diabetesAnand Thakarakkattil Narayanan Nair, Agata Wesolowska-Andersen, Caroline Brorsson, et al.
The Lancet. Diabetes & Endocrinology|December 17, 2022
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trialsAdem Y Dawed, Andrea Mari, Andrew Brown, et al.
Communications Medicine|September 24, 2025
XBP1 expression in pancreatic islet cells is associated with poor glycaemic control especially in young non-obese onset diabetes across ancestriesMoneeza K Siddiqui, Theo Dupuis, Ranjit Mohan Anjana, et al.
Diabetes|December 16, 2022
Identification of Genetic Variation Influencing Metformin Response in a Multiancestry Genome-Wide Association Study in the Diabetes Prevention Program (DPP)Josephine H Li, James A Perry, Kathleen A Jablonski, et al.
Diabetes Care|October 5, 2021
Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to SulfonylureasAdem Y Dawed, Sook Wah Yee, Kaixin Zhou, et al.
Diabetes Care|March 29, 2022
Response to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673-2682Adem Y Dawed, Sook Wah Yee, Kaixin Zhou, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Communications Medicine|October 4, 2023
Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic reviewKatherine G Young, Eram Haider McInnes, Robert J Massey, et al.
Diabetologia|March 5, 2022
Young-onset diabetes in Asian Indians is associated with lower measured and genetically determined beta cell functionMoneeza K Siddiqui, Ranjit Mohan Anjana, Adem Y Dawed, et al.
Diabetologia|April 26, 2022
Correction to: Young-onset diabetes in Asian Indians is associated with lower measured and genetically determined beta cell functionMoneeza K Siddiqui, Ranjit Mohan Anjana, Adem Y Dawed, et al.
Diabetes Care|March 20, 2019
Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by <i>SLC29A4</i>) and Organic Cation Transporter 1 (OCT1) (Encoded by <i>SLC22A1</i>) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT StudyAdem Y Dawed, Kaixin Zhou, Nienke van Leeuwen, et al.
Nature Medicine|May 9, 2022
Heterogeneity in phenotype, disease progression and drug response in type 2 diabetesAnand Thakarakkattil Narayanan Nair, Agata Wesolowska-Andersen, Caroline Brorsson, et al.
The Lancet. Diabetes & Endocrinology|December 17, 2022
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trialsAdem Y Dawed, Andrea Mari, Andrew Brown, et al.
Communications Medicine|September 24, 2025
XBP1 expression in pancreatic islet cells is associated with poor glycaemic control especially in young non-obese onset diabetes across ancestriesMoneeza K Siddiqui, Theo Dupuis, Ranjit Mohan Anjana, et al.
Diabetes|December 16, 2022
Identification of Genetic Variation Influencing Metformin Response in a Multiancestry Genome-Wide Association Study in the Diabetes Prevention Program (DPP)Josephine H Li, James A Perry, Kathleen A Jablonski, et al.
Diabetes Care|October 5, 2021
Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to SulfonylureasAdem Y Dawed, Sook Wah Yee, Kaixin Zhou, et al.
Diabetes Care|March 29, 2022
Response to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673-2682Adem Y Dawed, Sook Wah Yee, Kaixin Zhou, et al.
Pageof 5